Evidence map›Paper›PMID 36987665›Full record

ArticleCNS neuroscience & therapeutics2023

Temozolomide protects against the progression of glioblastoma via SOX4 downregulation by inhibiting the LINC00470-mediated transcription factor EGR2.

Wenyang Li, Ming Wang, Wenjia Ma, Ping Liu, Mingming Zhang, Jiarong He, Yan Cui

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Wenyang LiDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, Changsha, China.ORCID 0000-0001-6495-6966
Ming WangDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, Changsha, China.ORCID 0000-0001-6772-8299
Wenjia MaDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Ping LiuDepartment of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.
Mingming ZhangDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Jiarong HeDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Yan CuiDepartment of Neurosurgery, The Second Xiangya Hospital of Central South University, Changsha, China.ORCID 0000-0003-1234-222X
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTemozolomide is extensively applied in chemotherapy for glioblastoma with unclear exact action mechanisms. This article seeks to address the potential molecular mechanisms in temozolomide therapy for glioblastoma involving LINC00470.

methodsBioinformatics analysis was conducted to predict the potential mechanism of LINC00470 in glioblastoma, which was validated by dual-luciferase reporter, RIP, ChIP, and RNA pull-down assays. LINC00470 expression and the predicted downstream transcription factor early growth response 2 (EGR2) were detected in the collected brain tissues from glioblastoma patients. Following temozolomide treatment and/or gain- and loss-of-function approaches in glioblastoma cells, cell viability, invasion, migration, cycle distribution, angiogenesis, autophagy, and apoptosis were measured. In addition, the expression of mesenchymal surface marker proteins was assessed by western blot. Tumor xenograft in nude mice was conducted for in vivo validation.

resultsMechanistic analysis and bioinformatics analysis revealed that LINC00470 transcriptionally activated SRY-related high-mobility-group box 4 (SOX4) through the transcription factor EGR2. LINC00470 and EGR2 were highly expressed in brain tissues of glioblastoma patients. LINC00470 and EGR2 mRNA expression gradually decreased with increasing concentrations of temozolomide in glioblastoma cells, and SOX4 expression was reduced in cells by temozolomide and LINC00470 knockdown. Temozolomide treatment induced cell cycle arrest, diminished cell viability, migration, invasion, and angiogenesis, and increased apoptosis and autophagy in glioblastoma, which was counteracted by overexpressing LINC00470 or SOX4 but was further promoted by LINC00470 knockdown. Temozolomide restrained glioblastoma growth and angiogenesis in vivo, while LINC00470 or SOX4 overexpression nullified but LINC00470 knockdown further facilitated these trends.

conclusionConclusively, temozolomide repressed glioblastoma progression by repressing the LINC00470/EGR2/SOX4 axis.

Indexed as

Early Growth Response Protein 2GlioblastomaRNA, Long NoncodingSOXC Transcription FactorsAnimalsApoptosisCell Line, TumorCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticHumansMiceMice, NudeTemozolomideTranscription FactorsEarly Growth Response Protein 2EGR2 protein, humanRNA, Long NoncodingSOX4 protein, humanSOXC Transcription FactorsTemozolomideTranscription Factorsangiogenesisapoptosisautophagyearly growth response 2glioblastomaLINC00470SRY-related high-mobility-group box 4temozolomide

Identifiers

PMID36987665
PMCPMC10352878
OpenAlexW4361288145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.